Screener
Alnylam Pharmaceuticals ALNY Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value per share, 250,000 shares authorized; 133,734 shares issued and outstanding as of June 30, 2026; 132,376 shares issued and outstanding as of December 31, 2025 | 1,337 | 1,324 |
| Additional paid-in capital | 7,716,958 | 7,510,473 |
| Accumulated other comprehensive loss | (32,138) | (20,097) |
| Accumulated deficit | (6,332,039) | (6,702,524) |
| Total stockholders' equity | 1,354,118 | 789,176 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's common stock par value per share?
- Alnylam Pharmaceuticals (ALNY) reported common stock par value per share of $0.01 in Q2 2026.
- How has Alnylam Pharmaceuticals's common stock par value per share changed year-over-year?
- Alnylam Pharmaceuticals's common stock par value per share decreased by 0.0% year-over-year, from $0.01 to $0.01.
- What is the long-term trend for Alnylam Pharmaceuticals's common stock par value per share?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.
Ask your AI about Alnylam Pharmaceuticals's common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude